CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis
2012
PAX5, a B cell–specific transcription factor, is overexpressed through
chromosomal translocationsin a subset of B cell lymphomas. Previously, we had shown that activation of
immunoreceptor tyrosine-based activation motif(
ITAM) proteins and
B cell receptor(BCR) signaling by
PAX5contributes to B-lymphomagenesis. However, the effect of
PAX5on other oncogenic transcription factor-controlled pathways is unknown. Using a MYC-induced murine lymphoma model as well as MYC-transformed human B cell lines, we found that
PAX5controls c-MYC protein stability and steady-state levels. This promoter-independent, posttranslational mechanism of c-MYC regulation was independent of
ITAM/BCR activity. Instead it was controlled by another
PAX5target,
CD19, through the PI3K-AKT-GSK3β axis. Consequently, MYC levels in B cells from
CD19-deficient mice were sharply reduced. Conversely, reexpression of
CD19in murine lymphomas with spontaneous silencing of
PAX5boosted MYC levels, expression of its key target genes, cell proliferation in vitro, and overall tumor growth in vivo. In human B-lymphomas,
CD19mRNA levels were found to correlate with those of MYC-activated genes. They also negatively correlated with the overall survival of patients with lymphoma in the same way that MYC levels do. Thus,
CD19is a major BCR-independent regulator of MYC-driven
neoplastic growthin B cell neoplasms.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
77
References
68
Citations
NaN
KQI